Core Viewpoint - The strategic collaboration between Innovent Biologics and Takeda Pharmaceutical aims to accelerate the development of Innovent's next-generation IO and ADC therapies, with significant financial implications for Innovent [1][2] Group 1: Collaboration Details - Innovent Biologics announced a global strategic partnership with Takeda Pharmaceutical on October 22, focusing on the development of IBI363, IBI343, and IBI3001 [1] - The collaboration includes joint development of IBI363, with Takeda leading commercialization efforts in the U.S. and Innovent granting Takeda commercialization rights outside Greater China and the U.S. for IBI363 and IBI343 [1] Group 2: Financial Aspects - Innovent will receive an upfront payment of $1.2 billion, which includes a $100 million strategic equity investment, with total deal value potentially reaching $11.4 billion [2] - Takeda's investment will involve purchasing approximately 6.91 million shares of Innovent at a price of HKD 112.56 per share, representing a 29.53% premium over the previous closing price [2] - The funding allocation includes 80% for global pipeline clinical and preclinical projects and 20% for general corporate purposes [2]
港股异动 | 信达生物(01801)高开近10% 与武田制药达成全球战略合作 总交易额最高可达114亿美元